PROBENECID | A080966 | LANNETT CO INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Amendment to Suitability Petition from Rising Pharma Holdings, Inc. FDA-2025-P-5431 · 9 docket documents Rising Pharma Holdings, Inc. filed this amendment to suitability petition FDA-2025-P-5431 on November 11, 2025, responding to an FDA information request by submitting proposed product labeling for Probenecid Tablets USP 250 mg pursuant to 21 CFR 314.93(d) in order for the FDA to complete review of R | Suitability | 2025-11-12 | Open | Rising Pharma Holdings, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.6601
per ea
Lowest NADAC/Unit
$0.6601
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00527136701PROBENECID 500 MG TABLET | $0.6601 | EA | Generic | — | 2026-06-17 |
| 00527136710PROBENECID 500 MG TABLET | $0.6601 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.